Home
This site is intended for healthcare professionals

Precision Decisions in Metastatic Prostate Cancer: Module 1 Testing Implementing HRR testing in clinical practice

Share

Description

This program is supported by an independent education grant from Pfizer. This education program is only available to healthcare professionals in the USA.

Credits: AMA PRA Category 1 Credits™ (0.25.00 hours)

Type of activity: Enduring material (On-demand)

Launch date: September 16th 2026

Expiration date: December 31st 2027

Estimated time to complete this activity: 15 minutes

Prefer to read instead? Read our Key Clinical Summary here.

This is Module 1 of a three-part on-demand series: Module 2 and Module 3.

Activity Description

Join expert Dr. Andrew Laccetti, MD, MS, for a practical, case-based exploration of how to implement guideline-concordant homologous recombination repair (HRR) testing workflows and apply PARP inhibitor evidence to treatment selection in metastatic prostate cancer. This session examines how to navigate the complementary roles of germline and somatic testing, troubleshoot common diagnostic barriers, interpret complex genomic reports, and coordinate multidisciplinary care to manage toxicities and improve patient outcomes.

Session Highlights

  • Implement comprehensive homologous recombination repair (HRR) testing for all metastatic prostate cancer patients by integrating both germline and somatic testing modalities.
  • Navigate the clinical strengths and limitations of using archival tissue, metastatic biopsies, and circulating tumor DNA (ctDNA) to ensure optimal genomic sampling.
  • Interpret complex genomic testing reports to accurately identify actionable driver mutations, such as BRCA2, while avoiding unwarranted treatment based on variants of uncertain significance (VUS) or clonal hematopoiesis.
  • Overcome common operational barriers in testing workflows and utilize multidisciplinary care coordination to effectively sequence PARP inhibitors and manage treatment-related toxicities.

Who Should Participate?

This program is designed for healthcare professionals directly involved in the diagnosis, targeted treatment, and longitudinal management of patients with metastatic prostate cancer (mPC), who seek to implement guideline-concordant genomic testing and multidisciplinary care into routine clinical practice.

  • Oncology and Urology Practitioners (Academic and Community)
  • Oncology Nurses
  • Nurse Practitioners
  • Physician Assistants
  • Pharmacists
  • Genetic Counselors
  • Other Healthcare Professionals involved in the care and treatment of patients with mPC

Faculty

Dr Andrew Laccetti

Dr Andrew Laccetti is a Genitourinary Medical Oncologist at NYU Langone Health’s Perlmutter Cancer Center, specializing in prostate, kidney, bladder, and testicular cancers. His clinical and research interests focus particularly on prostate cancer across the disease spectrum, from localized to advanced metastatic disease. He is actively involved in clinical and health services research, investigating novel treatment strategies and approaches to improve quality of life. Dr Laccetti is also committed to advancing personalized, patient-centered cancer care and innovative remote-monitoring strategies to improve treatment outcomes and patient experience.

Continuing Education Information

Commercial support: This activity received monetary support through an independent education grant from Pfizer.

This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.

Disclosures

Dr Andrew Laccetti has disclosed financial relationships within the past 24 months with the following ineligible companies: Advisory Board Member: Bayer, Johnson& Johnson, Pfizer. Research Support: Bayer, JANUX, Johnson&Johnson, Novartis, Pfizer.

These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education.

Dr Laccetti does not intend to discuss non-FDA uses of drug products and/or devices only in relation to products for which he has no financial relationships.

AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible companies. All relevant financial relationships for anyone associated with the content of this activity were mitigated prior to the release of this program.

Activity Accreditation for Health Professions

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

System Requirements

Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

  • When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
  • Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.

Participation Costs

There is no cost to participate in this program.

This continuing education activity is active starting September 16th 2026, and will expire on December 31st 2027..

Estimated time to complete this activity: 15 minutes.

Learning objectives

By the end of this education. HCPs will be able to:

Implement standardized, guideline-concordant HRR biomarker testing workflows in patients with mPC:

  • Identify patients eligible for germline and somatic HRR testing, including non-BRCA mutations.
  • Determine appropriate timing and testing modality within the clinical pathway.
  • Interpret test results to inform eligibility for targeted therapies within real-world workflows.

Apply emerging clinical evidence on PARPi-based therapies to guide treatment selection and sequencing in mPC:

  • Interpret clinical data on efficacy, safety, and biological rationale for PARPi-based combination strategies.
  • Select appropriate patients for PARPi combination strategies across mCSPC and mCRPC.
  • Determine optimal sequencing of therapies based on disease stage, biomarkers, and patient factors.

Manage treatment-related toxicities and coordinate multidisciplinary care for patients receiving PARPi-based therapies:

  • Identify and mitigate common hematologic and gastrointestinal adverse events (AEs) associated with PARPi combination therapies.
  • Apply dose modification and supportive care strategies to maintain treatment continuity in practice.
  • Coordinate multidisciplinary input to optimize safety, adherence, and patient outcomes.

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

Prostate cancer is the most common cancer affecting men in Western nations. We see that there's around 300 to let's say 330,000 new cases diagnosed in the United States each year, which amounts to around 35-36,000 patients dying of the disease. Uh, in order to best optimize the outcomes for men with prostate cancer, uh, the, the sound utilization of homologous recombinant repair or HRR testing, uh, including BRCA mutations, is, is very important and is often being missed for patients that are candidates. 74% of clinicians lack confidence in HRR testing workflows and 89% lack confidence in treatment selection sequencing related to this testing, which is showing that many providers are in need of further guidance and um systems to help assure that we're getting the necessary testing and opening up the opportunities for the correct patients to get the correct treatments. All right. So, for our first objective here, implementing HRR testing in clinical practice, our learning objective will be to implement standardized guideline concord HRR biomarker testing workflows in patients with metastatic prostate cancer. So again, the practice gap as we reviewed before is that 74% of healthcare providers lack confidence in testing workflows and interpretation, and it's important for us to develop means to help improve upon this figure. All right. So here's our first polling question. Roughly what proportion of your patients with metastatic prostate cancer undergo HRR testing? A, fewer than 25%, B, 25 to 50%, C, 50 to 75%, and D, more than 75%. Very good. Um, so I think this is a, a very telling, uh, poll question. And for comparison, we see that under 50% of men with metastatic castration resistant prostate cancer are actually tested in the real world for HRR. So, this is something that many of us can improve upon. Um, and if you're doing better than that number, that, that's, that's excellent. You've built some good systems and workflows in your clinic, um, to best care for your patients. All right. We're gonna move on now and discuss the case. So, the patient described here is a 66-year-old man with an ECOG performance status of zero. He, unfortunately, has a newly diagnosed metastatic prostate cancer characterized by a PSA of 84, uh, as well as a prostate biopsy that showed Gleason 4 + 5 adenocarcinoma. On imaging, he had multiple osseous metastases and retroperitoneal nodes that were evident on PSMA PET. He has no family history of prostate cancer, breast, or ovarian cancer. So, the first question for the group is, what testing would you order at this point and when? So, options are we could send germline testing or spermatic testing or possibly both. Does it make sense to order it now at the initial time of diagnosis or do we wait until castration resistance? And then another important uh question is which sample would you use? Would it be the prostate biopsy or would you, would it be more appropriate to send a liquid biopsy uh to assess for circulating tumor DNA? And who in your service actually places this order? To continue our discussion, uh, every man with metastatic prostate cancer should have both germline and somatic testing. So this is well supported within NCCN as well as, uh, the American, um, Urology Association guidelines and ASCO guidelines that metastatic disease. Uh, it prompts both germline and somatic testing. So this is an important feature to realize. And, um, we even have some expanded testing to those patients that have node positive or high-risk localized prostate cancers uh for the germline component. Um, there is an opportunity to send somatic testing either on tumor, uh, uh, uh, biopsies or circulating tumor DNA, so a blood-based specimen. And um the reason why we do this is that 42% of men with pathogenic germline mutations uh would be missed if germline testings were restricted to high-risk patients uh under the NCCN criteria. So, um, you know, there are many patients that we would be missing if we weren't sending the germline testing on all patients with meta metastatic disease. Importantly, uh, it's also recommended for patients with metastatic disease to sustain microsatellite instability. Um, this is important for the selection of immunotherapy for those patients that are candidates. Now, um, you know, it's important to realize that not all patients will come back with candidate HRR mutations or MSI, uh, instability, but even a negative test is informative in selecting the appropriate, um, uh, treatment options for these patients. So again, germline and somatic testing are complementary. They're not alternatives. Uh, germline testing for review, this is testing normal healthy tissue in the body of the patient. This is generally done um by a blood specimen. At times, it can be done by saliva or actually, um, um, we've seen it, uh, it's in some centers, uh, done with a cheek swab. So we're looking to determine what genes patients um inherited. Um, uh, that may have put them at risk for their cancer. Um, somatic mutations on the other hand, these are, uh, this is a test done on the biopsy specimen itself or a blood-based specimen that's looking for circulating tumor DNA. Again, in interest of determining the specific mutations that are present in the tumor itself. So again, there's a two-hit hypothesis. There can be a first hit that's Seen in the germline and then a second hit that's uh seen in an inactivated uh gene within the tumor itself. Um, many of the, the treatments, in particular, the PARP inhibitors that we utilize, they are guided, uh, their use is guided by either germline, um, or somatic testing. So both, uh, tests are informative. BRCA2 is the most prevalent HRR alteration that we observe in uh hormone-resistant prostate cancer. We see it in approximately 13% of patients. Um, this is followed by ATM CDK12, and BRCA1. Uh, you know, there's a, a, a multitude of other HRR, uh, mutations that are observed in, in, in, uh, both hormone-sensitive and hormone-resistant disease. Um, and this again is very important, uh, to recognize in terms of therapy selection for patients with, uh, hormone sensitive and hormone, uh, resistant disease, uh, with respect to PARP inhibitors. HRR testing is now moving earlier in the treatment, uh, journey, um, but, uh, remains, still remains incomplete in its performance for hormone resistant disease in the US. Uh, so the figure here depicts the frequency of, uh, homologous recombinant repair mutation testing for patients with metastatic disease, um, between 2014 and 2022. So this data set again reiterates the fact that we're woefully underdiagnosing patients um in, in both the hormone resistant and hormone sensitive setting. So as of 2022, we are performing testing in about a third of patients with hormone sensitive disease and then uh another uh 5% in the castration resistant setting. Um. So, you know, this is uh an important uh slide to realize again, showing that many of us can do better. But importantly, the guidelines now do suggest the select sending of um uh HRR testing for castration-sensitive patients. Again, with FDA approved PARP inhibitor therapy strategies, it's also informative for prognostication and consideration of patients for clinical trials. So CTDNA can capture key alterations seen in metastatic tissue when when uh the tumor fraction is high. So the figure here is demonstrating that there's about an 80, uh uh about a 90% concordance between clinically actionable copy number calls in matched liquid and solid biopsies. So that is to say, when you're observing a mutation in a liquid biopsy specimen. There's high confidence that this specimen corresponds with the findings seen in a tissue-based specimen itself. The challenge of this is that negative CTDNA results are not always confident due to the fact, um, prostate cancer is regarded as a lower um uh CTDNA shedding tumor and particularly for patients with localized or low volume metastatic disease. The reliability that adequate CTDNA is being shed for um mutational testing.